Skip header and navigation

1 records – page 1 of 1.

Risankizumab (Skyrizi®) therapy for inflammatory bowel disease (IBD)

https://libcat.nshealth.ca/en/permalink/chpams38191
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
2345
Available Online
View Pamphlet
Risankizumab is a biologic medication. A biologic medication is a type of medication that treats inflammation. This pamphlet explains how risankizumab works, how it is given, and how long you can expect to take it. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Specialty
Gastrointestinal System
Medications
Abstract
Risankizumab is a biologic medication. A biologic medication is a type of medication that treats inflammation. This pamphlet explains how risankizumab works, how it is given, and how long you can expect to take it. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
2345
Less detail